View Item 

Show simple item record

Genetic Causes of Clopidogrel Nonresponsiveness: Which Ones Really Count?
dc.contributor.authorMomary, Kathryn M.en_US
dc.contributor.authorDorsch, Michael P.en_US
dc.contributor.authorBates, Eric R.en_US
dc.date.accessioned2012-05-21T15:47:04Z
dc.date.available2012-05-21T15:47:04Z
dc.date.issued2010-03en_US
dc.identifier.citationMomary, Kathryn M.; Dorsch, Michael P.; Bates, Eric R. (2010). "Genetic Causes of Clopidogrel Nonresponsiveness: Which Ones Really Count?." Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 30(3). <http://hdl.handle.net/2027.42/91111>en_US
dc.identifier.issn0277-0008en_US
dc.identifier.issn1875-9114en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/91111
dc.publisherWiley Periodicals, Inc.en_US
dc.publisherBlackwell Publishing Ltden_US
dc.subject.otherPharmacogeneticsen_US
dc.subject.otherCYP2C19en_US
dc.subject.otherABCB1en_US
dc.subject.otherClopidogrelen_US
dc.subject.otherCytochrome P450en_US
dc.titleGenetic Causes of Clopidogrel Nonresponsiveness: Which Ones Really Count?en_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Clinical, Social, and Administrative Sciences, University of Michigan College of Pharmacy, Ann Arbor, Michigan.en_US
dc.contributor.affiliationumDivision of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan Health Systemen_US
dc.contributor.affiliationotherDepartment of Pharmacy Practice, Mercer University College of Pharmacy and Health Sciences, Atlanta, Georgiaen_US
dc.contributor.affiliationotherDepartment of Pharmacy Servicesen_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/91111/1/phco.30.3.265.pdf
dc.identifier.doi10.1592/phco.30.3.265en_US
dc.identifier.sourcePharmacotherapy: The Journal of Human Pharmacology and Drug Therapyen_US
dc.identifier.citedreferenceVarenhorst C, James S, Erlinge D, et al. Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin‐treated patients with coronary artery disease. Eur Heart J 2009; 30: 1744 – 52.en_US
dc.identifier.citedreferenceMega JL, Close SL, Wiviott SD, et al. Cytochrome P450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354 – 62.en_US
dc.identifier.citedreferenceTrenk D, Hochholzer W, Fromm MF, et al. Cytochrome P450 2C19 681G>A polymorphism and high on‐clopidogrel platelet reactivity associated with adverse 1‐year clinical outcome of elective percutaneous coronary intervention with drug‐eluting or bare‐metal stents. J Am Coll Cardiol 2008; 51: 1925 – 34.en_US
dc.identifier.citedreferenceMega JL, Thakuria JV, Cannon CP, Sabatine MS. Sequence variations in CYP metabolism genes and cardiovascular outcomes following treatment with clopidogrel: insights from the CLARITY‐TIMI 28 genomic study [abstract]. J Am Coll Cardiol 2008; 51: A206.en_US
dc.identifier.citedreferenceCollet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009; 373: 309 – 17.en_US
dc.identifier.citedreferenceSimon T, Verstuyft C, Mary‐Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360: 363 – 75.en_US
dc.identifier.citedreferenceSibbing D, Stegherr J, Latz W, et al. Cytochrome P450 2C19 loss‐of‐function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J 2009; 30: 916 – 22.en_US
dc.identifier.citedreferenceGiusti B, Gori AM, Marcucci R, et al. Relation of cytochrome P450 2C19 loss‐of‐function polymorphism to occurrence of drug‐eluting coronary stent thrombosis. Am J Cardiol 2009; 103: 806 – 11.en_US
dc.identifier.citedreferenceIngelman‐Sundberg M, Sim SC, Gomez A, Rodriguez‐Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 2007; 116: 496 – 526.en_US
dc.identifier.citedreferenceKuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27: 383 – 91.en_US
dc.identifier.citedreferenceAngiolillo DJ, Fernandez‐Ortiz A, Bernardo E, et al. Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel. Arterioscler Thromb Vasc Biol 2006; 26: 1895 – 900.en_US
dc.identifier.citedreferenceFrere C, Cuisset T, Morange PE, et al. Effect of cytochrome P450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome. Am J Cardiol 2008; 101: 1088 – 93.en_US
dc.identifier.citedreferenceGeisler T, Schaeffeler E, Dippon J, et al. CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. Pharmaco-genomics 2008; 9: 1251 – 9.en_US
dc.identifier.citedreferenceSuh JW, Koo BK, Zhang SY, et al. Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. CMAJ 2006; 174: 1715 – 22.en_US
dc.identifier.citedreferenceHulot JS, Bura A, Villard E, et al. Cytochrome P450 2C19 loss‐of‐function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006; 108: 2244 – 7.en_US
dc.identifier.citedreferenceDuBuske LM. The role of P‐glycoprotein and organic anion‐transporting polypeptides in drug interactions. Drug Saf 2005; 28: 789 – 801.en_US
dc.identifier.citedreferenceTaubert D, vonBeckerath N, Grimberg G, et al. Impact of P‐glycoprotein on clopidogrel absorption. Clin Pharmacol Ther 2006; 80: 486 – 501.en_US
dc.identifier.citedreferenceZiegler S, Schillinger M, Funk M, et al. Association of a functional polymorphism in the clopidogrel target receptor gene, P2Y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease. Stroke 2005; 36: 1394 – 9.en_US
dc.identifier.citedreferenceCuisset T, Frere C, Quilici J, et al. Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600‐mg loading dose of clopidogrel in 597 patients with non‐ST‐segment elevation acute coronary syndrome. Thromb Res 2007; 120: 893 – 9.en_US
dc.identifier.citedreferenceAngiolillo DJ, Fernandez‐Ortiz A, Bernardo E, et al. Lack of association between the P2Y 12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease. Thromb Res 2005; 116: 491 – 7.en_US
dc.identifier.citedreferenceLiu TJ, Jackevicius CA. Drug interaction between clopidogrel and proton pump inhibitors 2010; 30: 275 – 89.en_US
dc.identifier.citedreferenceMega JL, Close SL, Wiviott SD, et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 2009; 119: 2553 – 60.en_US
dc.identifier.citedreferenceOestreich JH, Smyth SS, Campbell CL. Platelet function analysis: at the edge of meaning. Thromb Haemost 2009; 101: 217 – 19.en_US
dc.identifier.citedreferenceMahla E, Antonino MJ, Tantry US, Gurbel PA. Point‐of‐care platelet function analysis ready for prime time? J Am Coll Cardiol 2009; 53: 857 – 9.en_US
dc.identifier.citedreferenceWiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001 – 15.en_US
dc.identifier.citedreferenceCAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329 – 39.en_US
dc.identifier.citedreferenceYusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST‐segment elevation. N Engl J Med 2001; 345: 494 – 502.en_US
dc.identifier.citedreferenceSteinhubl SR, Berger PB, Mann JT III, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288: 2411 – 20.en_US
dc.identifier.citedreferenceAnderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non‐ST‐elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (writing committee to revise the 2002 guidelines for the management of patients with unstable angina/non‐ST‐elevation myocardial infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007; 50: e1 – 157.en_US
dc.identifier.citedreferenceKing SB III, Smith SC Jr, Hirshfeld JW Jr, et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol 2008; 51: 172 – 209.en_US
dc.identifier.citedreferenceReaume KT, Regal RE, Dorsch MP. Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence‐based recommendations for use. Ann Pharmacother 2008; 42: 550 – 7.en_US
dc.identifier.citedreferenceGurbel PA, Becker RC, Mann KG, Steinhubl SR, Michelson AD. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 2007; 50: 1822 – 34.en_US
dc.identifier.citedreferencePrice MJ. Bedside evaluation of thienopyridine antiplatelet therapy. Circulation 2009; 119: 2625 – 32.en_US
dc.identifier.citedreferenceAngiolillo DJ, Fernandez‐Ortiz A, Bernardo E, et al. Variability in platelet aggregation following sustained aspirin and clopidogrel treatment in patients with coronary heart disease and influence of the 807 C/T polymorphism of the glycoprotein Ia gene. Am J Cardiol 2005; 96: 1095 – 9.en_US
dc.identifier.citedreferencesanofi‐aventis and Bristol‐Myers Squibb. Plavix (clopidogrel) package insert. Bridgewater, NJ; 2009.en_US
dc.identifier.citedreferenceDesta Z, Zhao X, Shin JG, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002; 41: 913 – 58.en_US
dc.identifier.citedreferenceXie HG, Kim RB, Wood AJ, Stein CM. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol 2001; 41: 815 – 50.en_US
dc.identifier.citedreferenceKim KA, Park PW, Hong SJ, Park JY. The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance. Clin Pharmacol Ther 2008; 84: 236 – 42.en_US
dc.identifier.citedreferenceGiusti B, Gori AM, Marcucci R, et al. Cytochrome P450 2C19 loss‐of‐function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high‐risk vascular patients. Pharmacogenet Genomics 2007; 17: 1057 – 64.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
phco.30.3.265.pdf
Size:
186.9KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.